INTRODUCTION immunodeficiency virus
. In addition to their neurotropism, the lentiviruses all share the ability to infect The Lentivirinae cells of the immune system, particularly monocyte/macroHuman immunodeficiency virus type 1 (HIV-1), the causphages, and give rise to disease after latent periods of ative agent of AIDS, belongs to a neurotropic subfamily of months to years (130-132, 248, 261-264) . The lentiviruses retroviruses known as the Lentivirinae (140) . The term can be subdivided into two groups, those that induce immulentivirus was first used in 1954 by Sigurdsson to describe nodeficiency in their hosts and those that do not. The several infectious diseases that occurred in domestic sheep primate lentiviruses (HIV-1, HIV-2, and simian immunode- (338) . Members of the lentivirus subfamily include HIV-1, ficiency virus) and the feline immunodeficiency virus belong HIV-2, Maedi-visna virus, equine infectious anemia virus, to the subgroup referred to as immunodeficiency viruses.
caprine arthritis-encephalitis virus, bovine immunodefi-This group of viruses gives rise to a variety of diseases that ciency virus, feline immunodeficiency virus, and simian result from direct virus multiplication in cells and tissues as well as opportunistic infections that arise as a result of the immunocompromised state of the host. Diseases caused by Like other retroviruses, the lentiviruses all encode an RNA dependent-DNA polymerase (reverse transcriptase) (pol), group-specific antigens (gag), and envelope proteins (env) (59, 69, 380) . However, the genetic organization of lentiviruses is more complex than that of other retroviruses in that they encode several additional regulatory proteins (62, 69, 72, 79, 277, 306, 312, 317, 320, 344, 353, 386) (Fig.  1A) . In HIV-1, these proteins include Tat, Rev, Nef, Vif, Vpu, and Vpr.
Soon after the HIV-1 genome enters a cell, it is reverse transcribed by a virally encoded protein, reverse transcriptase. The double-stranded DNA copy of the HIV-1 genome is translocated to the nucleus, where it integrates into the genome of the infected cell. Transcription of early viral genes results in the production of multiply spliced mRNA species that encode the Tat, Rev, and Nef proteins (69, 70, 183, 286, 312, 347) . Unlike Nef, Vif, Vpu, and Vpr, Transactivation of HIV-1 Gene Expression A. 5 (68-70, 83, 183, 343, 347) . Tat functions to increase the expression of multiply spliced mRNAs and hence its own expression and the expression of both Rev and Nef (67, 68, 71, 73, 156, 228, 229, 231) . When Rev reaches a critical level, it binds to mRNA via a Rev responsive element and stabilizes the mRNA (74, 77, 109, 124, 222, 229-231, 312, 326-330) . This results in a shift from multiply spliced mRNA to singly spliced and unspliced mRNAs. The unspliced mRNA encodes the structural proteins of the virus, Gag and Pol, and the singly spliced message encodes the auxiliary proteins Vif, Vpr, and Vpu. The function of many of the auxiliary proteins is unclear. Both Vif and Vpu have been shown to enhance maturation and release of infectious HIV-1 particles from the cell (62, 70, 352, 387) . Recent evidence has shown that expression of Vpu results in degradation of the CD4 glycoprotein (378) . Vpr appears to be a particle-associated regulatory protein (60, 61, 277) . The role of Nef is not clear. Several groups have reported that Nef has no effect on viral gene expression or replication, while others have reported that Nef negatively regulates gene expression (3, 15, 48, 151, 192, 269) . In addition, Nef expression has been correlated with a down-regulation of CD4 expression on the surface of infected T cells and has been shown to inhibit NF-KB induction of the HIV-1 long terminal repeat (LTR) (123, 269) . Recently, the Nef gene was cloned directly from peripheral blood of two HIV-1-infected individuals and inserted into an infectious molecular clone of HIV-1 (87) . The presence of the naturally occurring Nef gene was found to accelerate HIV-1 replication in primary human T cells but not in T-cell lines, suggesting that Nef plays an important role in the virus life cycle in vivo (87) . In addition, Nef mutants of simian immunodeficiency virus have been shown to replicate inefficiently in rhesus monkeys and fail to induce disease in those animals (189) .
Several cellular transcription factors are also important in the regulation of HIV-1 gene expression (69, 70, 73, 182, 250, 366, 383) . The 5' LTR of HIV-1 contains binding sites for several transcription factors, including NF-iB, SP1, EBP-1, LBP-1, UBP-2, and CTF/NF-1 (182, 366, 383) (Fig. 1B) . The transcription factor SP1 is expressed ubiquitously in cells and has been shown to function in the basal activity of the HIV-1 promoter (155, 182, 284) . LBP-1 and CTF/NF-1 have been postulated to function in the basal activity of the promoter. The functions of EBP-1 and UBP-2 are not known. NF-KB is an inducible transcription factor that is associated with reactivation of HIV-1 from chronically infected cells by phorbol esters and various cytokines, including tumor necrosis factor alpha (TNF-a) and interleukin-l,B (IL-1i) (14, 186, 209, 260, 361, 366) .
Unlike most other retroviruses, the lentiviruses, including HIV-1, do not require dividing cells for multiplication; rather, they multiply in cells that are terminally differentiated or activated (131, 132, 149, 359, 373) . Lentiviruses that can replicate in T lymphocytes, however, maintain a requirement for T-cell activation as well as T-cell proliferation.
CLINICAL MANIFESTATIONS OF HIV-1 INFECTION OF THE CENTRAL NERVOUS SYSTEM (CNS)
Acute HIV-1 Meningitis and Meningoencephalitis HIV-1 enters the nervous system shortly after infection (116, 126, 162, 308, 350) . In one case of an iatrogenic infection, HIV-1 was demonstrated in the brain within 2 weeks (80). In the majority of acutely infected persons, entry of HIV-1 into the brain is either clinically silent or unrecognized, but on occasion an acute meningitis or meningoencephalitis may occur. These illnesses generally develop 3 to 6 weeks after primary HIV-1 infection. Not infrequently, acute neurological complications of HIV-1 infection develop in tandem with an illness resembling infectious mononucleosis and is characterized by sweats, rigors, arthralgias, myalgias, nausea and vomiting, sore throat, abdominal cramps, and diarrhea. Fever, generalized lymphadenopathy, pharyngeal injection, splenomegaly and splenic tenderness, maculopapular rash, and urticaria are observed on physical examination (64, 162) . Laboratory studies may reveal transient thrombocytopenia and lymphopenia with an inversion of CD4/CD8 (helper/suppressor) lymphocyte ratio. This acute illness is seldom recognized as a consequence of HIV-1 infection. Furthermore, serological tests for the presence of HIV-1 antibodies are typically not positive during this stage of infection, requiring an average of 8 to 12 weeks from the time of infection for their detection. Transient HIV-1 antigenemia that precedes the development of detectable HIV-1 antibody by 6 to 8 weeks and that lasts 3 to 4 months may be seen with acute infection (143) . In addition to measuring HIV-1 p24 antigen, viral culture and the use of polymerase chain reaction to detect HIV-1 provirus may be helpful in diagnosing the HIV-1 infection prior to seroconversion (379) .
The meningitis (162, 165) or meningoencephalitis (45) that supervenes is characterized by headache, meningismus, photophobia, generalized seizures, and altered mental state. On rare occasions, other neurological complications may accompany acute HIV-1 infections, including ataxia (33, 323) , cranial neuropathies (171), acute meningoradiculitis (285), acute myelopathy (85), cauda equina syndrome (389) , and brachial plexitis (33, 41) . In the face of acute HIV-1 meningitis or meningoencephalitis, cerebrospinal fluid (CSF) examination usually reveals an increased protein (<100 mg/100 ml), mononuclear pleocytosis (<200 cells per mm3), and normal glucose (165) . CSF viral cultures or viral antigen studies may establish the diagnosis before the development of either a systemic or a local antibody response. However, neither the presence of HIV-1 in the CSF by culture or antigen assay (296) nor the demonstration of intrathecal antibody synthesis specific for HIV-1 necessarily indicates the coexistence of clinically symptomatic neurological disease. Viral recovery from the CSF (118) may be as common in the absence of neurological disease as in its presence. Similarly, intrathecal HIV-1-specific immunoglobulin G synthesis during early infection occurs commonly in asymptomatic HIV-1-seropositive individuals (97, 308) .
A small percentage of individuals with HIV-1 meningitis will present in subacute fashion and have features of the illness that persist for months. Hollander and Stringari (165) proposed that two forms of meningitis may accompany HIV-1 infection. In a study of 14 patients with relatively preserved immune function, an unexplained CSF lymphocytic pleocytosis was associated with an acute, self-limited meningitis in seven patients and chronic headaches with or without meningeal signs in the other seven patients (165) . In four of five CSF specimens studied, HIV-1 was recovered (165) . The investigators concluded that, in addition to the acute HIV-1 meningitis associated with recent seroconversion, sporadic episodes of acute and chronic meningitis may complicate HIV-1 infection (165) . Even in the absence of any symptoms, abnormal CSF findings are very common in HIV-1-infected individuals (7, 46, 97, 235, 236 antigen (296) do not appear to be predictive of the subsequent development of clinically manifested neurological disease (236) .
HIV-1 Encephalopathy (HIV-1-Associated
Cognitive-Motor Complex) Shortly after the initial description of AIDS, an unusual, slowly progressive, dementing illness was recognized in association with this disease (34, 342) . This disorder was at first referred to as a subacute viral encephalitis, and cytomegalovirus was considered the likely etiology (34, 270, 342) . Subsequently, compelling evidence accumulated directly linking HIV-1 to this encephalopathy. This illness has been referred to by several appellations, including AIDS dementia complex, AIDS dementia, AIDS encephalopathy, and HIV-1 encephalopathy. Because of the spectrum of abnormalities observed in association with this disorder, a Working Group of the American Academy of Neurology chose the name HIV-1-associated cognitive-motor complex to include patients with severe manifestations as well as individuals with milder illness (176, 381) . The distinction between the mild cognitive deficits associated with HIV-1 infection and clinically evident dementing illness is significant since it is uncertain whether these disorders exist on the same continuum.
The exact incidence of this disorder in HIV-1-infected individuals remains uncertain. Of (300, 301) . These investigators (266) (307) . The development of effective antiretroviral therapy, such as zidovudine, may have altered the natural history of this disorder and changed the frequency with which it is observed (82, 295) . A fivefold decline in the annual incidence was noted in one population following the introduction of zidovudine (295) . A phase II placebo-controlled study of zidovudine in patients with AIDS and AIDS-related complex suggests that the annual rate of clinical dementia in patients with Centers for Disease Control stage IV disease is approximately 14% (82) . Recent data from the multicenter AIDS cohort study suggest that the incidence of dementia after the development of AIDS is approximately 7% annually, with approximately one-third of patients being demented at the time of death (321) .
The incidence of HIV-1 encephalopathy determined at autopsy has varied among different series. In a study of the findings of 345 consecutively performed autopsies of patients dying with AIDS, 68 (19%) had morphological features of HIV-1 encephalopathy (198) . In a large series incorporating seven separate neuropathological studies (206) that comprised 926 patients, the estimates for HIV-1 encephalopathy ranged from 13.3 to 62.9%, with a composite total of 30.9%. Navia and colleagues have suggested that as many as twothirds of autopsied AIDS patients have this encephalopathy (265) , whereas other investigators have found a higher incidence, between 70 and 93% (84, 145, 148, 184, 197, 270) . A study from San Diego, Calif., of 107 brains from autopsies of patients with AIDS, which were collected during a 3-year period, revealed that while only 16% had the characteristic hallmarks of HIV-1 encephalitis, more than 50% had evidence of HIV-1 infection (238).
Overt HIV-1 Encephalopathy Clinically, HIV-1 encephalopathy is characterized by an insidious onset of a disturbance in intellect. Fatigue and malaise, headaches, increasing social isolation, and loss of sexual drive are noted. Rarely, the disorder may begin abruptly and progress rapidly. Patients often complain of increasing forgetfulness, difficulty concentrating and reading, and a slowness in their thinking. Job performance declines, and eventually self-care may become problematic. A diagnosis of depression is frequently considered. However, dysphoria is typically absent (301) . Language skills suffer and word finding difficulties are common. Some patients complain of incoordination, imbalance, gait disturbances, or tremor. Painful peripheral dysthesias may occur and are typically the result of a superimposed HIV-1-related peripheral neuropathy.
Sleep disturbances are reported, with polysomnographic studies indicating a distortion of sleep architecture (271, 272) , and both focal and generalized seizures have been described (19, 168, 283) . In fact, in a large percentage of HIV-1-infected persons with seizures, no etiology other than HIV-1 could be identified for the seizures (19, 168) .
HIV-1 encephalopathy typically occurs in the context of advanced immunosuppression and coexistent systemic disease (136, 139, 300, 301, 333, 339, 364) (22, 52, 267) . Approximately 3% of adults with AIDS present with dementia (177, 242, 267) .
The typical patient with overt HIV-1 encephalopathy appears debilitated and chronically ill as a consequence of advanced immunosuppression. Physical examination often reveals the hallmarks of full-blown AIDS with temporal and general body wasting, alopecia, seborrheic dermatitis, and generalized lymphadenopathy. Bedside mental status examination in advanced HIV-1 encephalopathy reveals a slowing of mental processing (bradyphrenia). Eye movement abnormalities are common. These ocular motility disorders include slowed saccadic eye movements (252, 268, 315) , hypometric saccades (76), overshoot dysmetria (114), fixational instability (76) , and defective smooth pursuits (76) . Currie and colleagues found these eye movement abnormalities useful predictive markers for the development of HIV-1 encephalopathy (76) . There is a diminution of facial expression (facial hypomimia). The voice is hypophonic and monotonous, and speech production is typically slow. Stuttering has also been reported (107) . Coordination is impaired, consistent with involvement of the basal ganglia (8) . This impairment may be observed even in early stages of the illness (8) . Fine movements are performed slowly and awkwardly. Such tasks as buttoning shirts, writing, cutting food, and shaving may prove difficult (313) . A fine, irregular tremor that is most evident during sustained postures of the upper limbs is frequently detected. A resting tremor is not observed though features reminiscent of Parkinsonism, namely, bradykinesia, postural instability, cogwheel rigidity, hypomimetic facies, and eye movement disorders, may be observed. The motor tone is increased. The gait is slow and clumsy with diminished arm swing and postural instability. In early stages of HIV-1 encephalopathy, brisk walking, pivoting, and walking heel-to-toe may betray abnormalities (313) . Parkinsonian features may be intensified by the administration of dopamine receptor blockers, including prochlorperazine and metoclopropamide (93, 164, 170) , and the patient may literally be "frozen" in bed as a consequence. Dystonia has been reported in the absence of neuroleptic exposure (253) . Muscle (24, 103) . As in adults, the neurologic manifestations may occur before any signs of immunodeficiency, exemplified by the infant described by Davis and coworkers who developed progressive spastic diplegia and dementia at the age of 6 months resulting from HIV-1 infection in the absence of any evidence of immunosuppression (81) . However, generally, the neurologic disease progresses in tandem with the degree of immunodeficiency (104) . In one study of 36 infected children, the incubation period from initial perinatal infection to the development of encephalopathy varied from 2 months to 5 years (104 (22, 75) . In perhaps 10 to 15% of the affected individuals, the illness may present as a frank psychosis. A triad of mood disturbance, thought disorder with grandiose delusions, and severe memory deficits has also been described (190) . Sim (288) . The possibility of a drug-induced psychiatric disorder should not be readily discounted. Mania in association with zidovudine (382) and aggressive psychosis with corticosteroid administration (42) by some investigators to be a pathologic hallmark of the disease, but others observe this only rarely (5, 6) . The multinucleated giant cells appear to result from direct virusinduced cell fusion (301) . This phenomenon appears to be identical to one that occurs in vitro in HIV-1-infected cell cultures (294) . These multinucleated giant cells appear to (11) . Increasing interest has focused on cortical changes occurring as a consequence of HIV-1 infection. Early studies (36, 84) described cortical abnormalities in the brains of adults with AIDS, and nerve cell loss was detected in affected children (333) . Using quantitative techniques, Wiley and colleagues have demonstrated significant thinning of the neocortex in patients with HIV-1 encephalopathy (376). In addition to the loss of neurons, these investigators showed a loss of synaptic density and vacuolation of dendritic processes (238, 376) . The dendritic and synaptic damage has been correlated with the presence of HIV-1 in the neocortex (239) . In other studies, quantitative assessments of neurons in the frontal cortex have revealed a significant decrease in their numbers in HIV-1-infected brains compared with control brains (106) . Isolated cases of prominent cortical atrophy with neuronal loss (145) and massive neuronal destruction accompanied by diffuse necrotization (135) (37) . Generally, a broad spectrum of neuropathological findings that include features of these pathological syndromes exist. In children, the pathologic features of HIV-1 encephalopathy occur as a unique constellation characterized by diminished brain weight, inflammatory cell infiltrates, multinucleated giant cells, vascular calcifications, perivascular inflammation, and white matter changes (334) . At autopsy, the brains of children with HIV-1 infection weigh less than those of normal controls (202) . Although multinucleated giant cells, microglial nodules, and white matter pallor are commonly observed in the brains of children and adults, the most frequent finding in children is vascular or juxtavascular basophilic mineralization located in either the basal ganglia (putamen and globus pallidus, but not caudate) or the frontal lobe white matter (333) . This mineralization of the basal ganglia is detectable on radiographic imaging and appears to be unique to childhood HIV-1 encephalopathy (23, 334) . Inflammation of parenchymal blood vessel walls (cerebral vasculitis) has been observed in approximately 30% of the brains of children with HIV-1 infection (333) . As in adults, the genome of HIV-1 can be demonstrated in the brains of these patients by in situ hybridization techniques (305, 334) .
Just as the frequency of clinically detected AIDS dementia is changing (295) , the frequency and pattern of neuropathology are changing (310). In 300 consecutive autopsies of patients with AIDS, Rhodes and Ward noted a continuing linear decrease in the presence of gliomesenchymal cell nodules and chronic perivasculitis (310) . They attributed these decreases to the use of antiretroviral therapy, in particular, zidovudine (310) . However, during the 3-year course of their series, they noted an increase in the incidence of perivascular macrophages and multinucleated giant cells (310) .
NEUROTROPISM OF HIV-1
Evidence for Direct Infection of the CNS by HIV-1 Direct infection of the nervous system by HIV-1 was not appreciated in the early years of the AIDS epidemic. Neurological complications associated with AIDS were largely attributed to opportunistic infections and depression. , by sequence similarity and morphological criteria, HIV-1 was classified as a lentivirus (140, 306, 320, 344) . In that same year, HIV-1 DNA and RNA were detected by Southern blot and in situ hybridization in 5 of 15 brains from patients with AIDS (337) . Also in that year, Epstein and colleagues detected retrovirus-like particles in the brains of three patients with AIDS by using electron microscopy (102) . These particles were localized to multinucleated giant cells and occasionally to astrocytes (102 (16) (17) (18) .
T-Cell-Versus Macrophage-Tropic Strains
The selective depletion of CD4+ T lymphocytes in AIDS patients together with the finding that HIV-1 could productively infect this population of cells in vitro clearly established CD4+ T cells as a primary site of HIV-1 replication (20, 121, 195, 245, 294) . The subsequent demonstration that CD4 functioned as the cell surface receptor for HIV-1 explained the tropism of the virus for these cells (78, 194, (244) (245) (246) . The rate of viral multiplication and concomitant cell death in these cultures was correlated with the state of activation of the T cells (245) . T (50) . Changes in the molecular weight of gpl20 were correlated with these changes (50) . Similar to what had been shown for other members of the lentiviral subfamily (130) (131) (132) 264) , HIV-1 was also shown to infect cells of the monocyte/macrophage lineage (126, 127, 129, 233, 248, 292, 293) . Virus binding and infectivity of these cells also depended on expression of the CD4 receptor (63, 221, 232, 233) . In many instances, the replication of HIV-1 in macrophages and in macrophage-derived cell line cultures was very inefficient compared with the growth of the virus in primary T cells and T-cell lines. This restricted activity was not dependent on levels of CD4 as many of the macrophage cell lines expressed higher levels of CD4 than their T-cell counterparts. In fact, different isolates of HIV-1, often from the same patient, varied in their tropisms for different cell types (4, 12, 50, 51, 54, 147, 150, 191, 371) . In general, HIV-1 isolated from AIDS patients early in disease replicated less efficiently and had a narrower host range in cell culture than HIV-1 isolated from the same patients at later stages of the disease (12, 54, 110) . Often, strains of HIV-1 that infected T cells efficiently grew less well or not at all in macrophage cultures and strains that grew well in macrophage cultures were less efficient in T-cell cultures. This observation led to the identification of T-cell and macrophage-tropic variants of HIV-1. A summary of these different strains, their primary sites of isolation and passage histories, and the cells that they infect is given in Table 2 .
Viral and Cellular Determinants of Tropism Investigation into the viral determinants of T-cell tropism showed that the binding of virus to the CD4 molecule was mediated by gpl20, the product of the env gene of HIV-1 (388) . The env gene of HIV-1 encodes a 160-kDa precursor protein that is cleaved by a viral protease into a surface unit monomer of 120 kDa (gpl20) and a transmembrane species (gp4l). Antibody mapping studies and site-directed mutagenesis have precisely defined the regions on both the gpl20 and CD4 molecules that are necessary for binding of virus to CD4+ cells (9, 66, 208 (43) .
Detailed analysis of T-cell and macrophage-tropic variants of HIV-1 identified additional regions outside of the CD4-binding site of gp120 as important determinants of viral tropism (172, 174, 221, 275) . Specifically, changes in the V3 loop region of the gpl20 molecule were implicated (172, 174) . It has been proposed that the V3 loop serves as a substrate for a cell surface protease whose action aids in the fusion of the viral envelope to cells. Therefore, changes in this region could affect tropism by altering the recognition site on the V3 loop for this protease (57, 128) . In support of this idea is the demonstration by Robinson and colleagues that the efficiency of viral fusion and entry into cells is an important factor in determining tropism (346) . A third important region of the virus in determining tropism resides in a 41-kDa transmembrane protein associated with gpl20. Changes in this region have also been found to alter the host range of HIV-1 (115).
Tropism of Virus Isolates Obtained from Neural Tissue Several laboratories have reported the direct isolation and characterization of HIV-1 from the CNS (4, 50, 54, 201) .
Similar to what had been observed of viruses isolated from peripheral blood, the CNS-derived isolates were found to differ in their tropism for different cell types. In one study, an isolate derived from CSF (JR-CSF) grew well in peripheral blood lymphocytes (PBL) but did not grow efficiently in primary macrophage cultures (201) . Another isolate derived from the frontal lobe of the same patient (JR-FL) grew well in both PBL and macrophage cultures (201) . Interestingly, only the CSF-derived isolate was able to infect explants of a brain glioma. The infection in the glioma explant culture was characterized as a low-level persistent infection (201 (110) . Several groups have also reported that virus isolated from CSF and blood can be distinguished genotypically by differences in restriction enzyme digest patterns (150, 201 (361) . These cells could also be infected with cell-free virus. The infection was characterized by an initial burst of viral p24 production that declined over time. Viral p24 could be detected several weeks later when the cultures were cocultured with uninfected T cells (361) . It was shown that cell-to-cell contact was not necessary for the reappearance of infectious virus because a similar effect was seen when the cells were separated by a semipermeable membrane. The cytokines TNF-ao and IL-113 were found to mimic the effect of coculturing the glial cells with the T cells (13, 361) . The authors suggested that glial cells could be an unidentified reservoir of HIV-1 in the CNS and that infiltrating lymphoid cells or macrophages could reactivate latent HIV-1 in these cells.
The cellular receptor for HIV-1 on lymphoid cells and microglial cells, CD4, has not consistently been demonstrated on cells of neuronal origin. In addition, antibodies to CD4 and soluble forms of CD4 that block the infectivity of HIV-1 in lymphoid cells do not block infection of neuronal cells (56, 205, 371, 375) . The lack of the CD4 receptor on neural cells cannot wholly account for the slow growth of HIV-1 in these cell types as transfection of the cells with viral DNA does not result in improved viral replication. In addition, Harouse and colleagues recently demonstrated that the replication kinetics of HIV-1 in glial cells constitutively expressing CD4 did not differ from their non-CD4-expressing counterparts (154) . They also showed that the efficiency of virus entry into these cells was the same whether or not the cells expressed CD4 (154) . Several groups have shown recently that galactocerebrosides may serve as receptors for HIV-1 on CD4-negative cells, including astrocytes and colon epithelial cells (28, 152, 384) . In these studies, antibodies to galactocerebrosides inhibited the entry of HIV-1 into cells, and in one study, recombinant gpl20 specifically interacted with galactocerebroside (28).
MECHANISMS OF HIV-1 DAMAGE TO THE CNS
The fact that HIV-1 causes damage in the CNS has been documented in numerous reports of the clinical consequences of finding HIV-1 virions in brain (199) and spinal cord (85, 161, 314) . Unlike other virus infections in the CNS, the mechanisms of HIV-1 damage have eluded investigations since there is little evidence that HIV-1 directly infects neural cells. This observation has prompted the suggestion that virus damage either occurs because of direct infection of a relatively small population of cells that may be difficult to detect or is caused by indirect effects following release of neurotoxic factors from infected non-neural cells such as macrophages. (376) , axonal loss in the optic nerve (357) , and particularly interneuron loss in the hippocampus (239) . Human fetal or adult neurons in culture derived from either the CNS or the peripheral nervous system also do not appear susceptible to HIV-1 infection (205, 361) . Recently, however, the HIV-1 LTR from isolates from either frontal lobe or CSF, JR-FL or JR-CSF, respectively, was expressed in the brains of transgenic mice, particularly in neurons (65) . The HIV-1 LTR of a lymphotropic strain was not expressed in CNS tissues in this study, which correlates with other reports (212, 341, 367 (265) . However, there is no evidence of direct infection of the myelin-producing oligodendrocytes in the CNS by HIV-1 (265 (125) . Partial sequence homology of the transmembrane envelope viral protein, gp41, shows similarities to scorpion peptide, particularly in its ability to interact with cellular surface molecules involved in ion-gated channels. In VOL. 6, 1993 on October 27, 2017 by guest http://cmr.asm.org/ Downloaded from a glial cell model of infection, the Nef protein can be synthesized in different antigenic forms, and it has been suggested that this might play a role in the establishment of viral latency in these cells (200) .
The major HIV-1 regulatory protein, Tat, has a clear function in transactivation of early genes for viral transcription as well as effects on host cell transcription (70) . There is one report that Tat is able to induce cytopathic effects in cultured rodent glioma and neuroblastoma cells and to affect rat brain synaptosomal membranes (224, 319) . Binding of Tat affects membrane permeability, causing depolarization and altering membrane resistance. Since Tat is secreted from infected cells and can diffuse into neighboring cells (113) , it is possible that it can alter cellular functions in cells in which it is not synthesized.
Effects of Structural HIV-1 Proteins
Experiments involving HIV-1 binding and its consequences have been emphasized in attempts to understand mechanisms of neuronal injury in HIV-1 infection. The envelope proteins have received significant attention in these experiments, particularly the gp120 outer surface molecule that interacts with the cellular CD4 receptor. In one of the first series of experiments, similarities of gpl20 and neuroleukin were identified by competition for similar cell surface receptors. In these studies, gpl20 could inhibit the growthpromoting properties of neuroleukin for chick dorsal root ganglion sensory neurons (210) . The viral gpl20 was also shown to be toxic to mouse hippocampal neurons in culture (29) . Vasoactive intestinal peptide, which has sequence similarity to the CD4-binding domain of the gpl20 molecule, blocked the toxic effects of gpl20 on these cells (29) . The toxicity of gpl20 for these cells was most pronounced when astrocytes were also present in the culture, suggesting that the toxicity could be related to some other factor released from infected cells (29) .
Some of the strongest evidence for neurotoxicity of the gpl20 molecule comes from experiments in which rodent hippocampal neurons or retinal ganglion cells show cell loss due to increases in intracellular Ca + (89) . Only the glycosylated form of gpl20, whether derived from a neurotropic or a lymphotropic strain, was toxic in these assays. Calcium channel antagonists such as nimodipine and nifedipine block this effect (89) . This type of neuronal injury may be similar to that of excitatory amino acids of the glutamate type on N-methyl-D-aspartate (NMDA) receptors. However, it appears that gpl20 and glutamate act synergistically to induce toxicity (220) . A further test of the association between gpl20 toxicity and NMDA receptors showed that an NMDA antagonist, 1-amino-3,5-dimethyladamantine (Memantine), could block the toxicity of gpl20 (219) . Antagonists to the NMDA receptor, such as D-2-aminophosphonovalerate, also inhibit toxicity of nonviral factors secreted by HIV-1-infected monocytes and macrophages (137) . These experiments, however, do not prove that gpl20 needs to bind directly to the NMDA receptor. Mechanisms that explain toxicity could involve other molecules that interact with gpl20 at sites proximal to the NMDA receptor. In experiments with rat fetal brain cell cultures, gpl20 was not toxic by itself but only in combination with cell culture fluids contaminated by mycoplasmas or lipopolysaccharide (27 (Fig. 3) . The targets of the cytokines within the CNS include cells of both neuronal and glial origin (Fig. 3) . Similarly, resident cells of the nervous system may elaborate cytokines that target cells of the immune system that traffic through the CNS (Fig. 3) .
While there is a great deal of in vitro evidence that TNF-a, IL-1,B, and IL-6 are secreted by both astrocytes and microglial cells, relatively little is known about the role of cytokines in normal physiologic signaling and communication between cells of the CNS (Fig. 3 ). In the developing rat nervous system, microglial cells are a major source of in the perinatal period (138) . Given the observation that IL-13 is an astroglial growth factor, it has been proposed that microglia may regulate astroglial growth during maturation of the nervous system. TNF-a similarly has been implicated to have a role in brain development (385) . In the mature nervous system, much of the work on cytokines has focused on their role in modulating the hypothalamus. IL-13, TNF-a, and IFN--y all exhibit intrinsic pyrogenic activity by acting directly on the thermoregulatory centers of the anterior hypothalamus (372) . This endogenous pyrogenic activity is mediated by prostaglandin E2 synthesis within the hypothalamus (58) . IL-1B is also able to provide feedback to the immune system indirectly by stimulating the murine hypothalamic-pituitary-adrenal axis, leading to increased production of corticotropin-releasing factor and subsequent secretion of immunosuppressive glucocorticoids (355) . Excitation of the sympathetic pathway, which also originates in the hypothalamus and has nerve terminals in lymphatic organs, is yet another proposed mechanism by which IL-1l is able to provide feedback to the immune system (180) . Lastly, IL-113 may also exert influence on satiety and the sleep-wake cycle, again by acting at the level of the hypothalamus (92). In the peripheral nervous system, very little is known about the role cytokines play. However, one study did demonstrate that non-neuronal cells of the rat sciatic nerve produce markedly increased levels of nerve growth factor in the presence of IL-1i (218) .
Role of Cytokines in Injury and Infection
In response to injury and infection, cytokine production within the CNS has been proposed to cause a myriad of changes. The changes that may have some relevance to HIV-1 infection can be summarized as follows. levels detectable in the CSF (368) . TNF-a causes a breakdown of the blood-brain barrier with resultant meningeal and parenchymal edema and further leukorrhea (259) . Viral meningitis, in contrast, is not associated with elevated levels of TNF-a (211) . (ii) In vitro, TNF-a induces oligodendroglial demise (311) , and in vivo, TNF-a-positive cells (astrocytes and macrophages) have been found at the edge of multiple sclerosis plaques (163) , suggesting that TNF-a-producing cells may play a role in demyelinating diseases. (iii) TNF-a is also able to induce expression of major histocompatibility complex class I proteins on astrocytes and oligodendrocytes, potentially exposing these cells to the toxic effects of trafficking cytotoxic T cells (241) . (iv) Lastly, TNF-a and IL-11 have been demonstrated to promote astrocyte proliferation (207) . The role of these four mechanisms in the neuropathogenesis of HIV-1 infection is discussed below.
In Vivo Evidence for the Role of Cytokines in HIV-1-Associated Neuropathology In 1989, Gallo and colleagues (119) examined the CSF of 38 HIV-1-infected patients for evidence of cytokine activation. Fifty-eight percent of the patients had elevated IL-1,B levels, 42% had elevated IL-6 levels, and none had detectable IL-2 levels. The elevations of IL-1 and IL-6 were not correlated with clinical signs of CNS involvement. Interestingly, the investigators were unable to detect elevated CSF TNF-a levels in any of these patients, including 16 patients with opportunistic infections. While a second group also failed to detect TNF in CSF of 28 HIV-1-infected individuals (336), a third group found that 25 of 45 patients had elevated CSF levels of TNF-a (146) . The discrepancy between the findings of these groups has been ascribed to technical differences in measuring TNF-a. Grimaldi and colleagues also found that elevation of CSF TNF-a levels correlated with the presence of opportunistic infection of the CNS (146) . The TNF-a levels were higher in CSF than in serum, further suggesting intrathecal production of the cytokine. No correlation was found between elevated TNF levels and the presence of HIV-1-associated dementia. In a study of pediatric AIDS encephalopathy (256), 11 of 26 children had elevated CSF TNF-a levels, but again, no correlation was found with the presence of progressive encephalopathy. Interestingly, elevated serum TNF-a levels were associated with the presence of encephalopathy, suggesting that circulating TNF-a may be responsible for the leukoencephalopathy associated with pediatric progressive encephalopathy.
The evidence from CSF studies clearly indicates that HIV-1 infection is associated with activation of the cytokine cascade in the meninges. However, while the CSF findings are an accurate reflection of meningeal pathology, they do not necessarily reflect pathology of the parenchyma. This is particularly true for HIV-1 infection, in which the majority of the parenchymal pathology is subcortical and therefore not directly accessible to the CSF. Tyor et al. (363) examined frozen sections taken at the time of autopsy of the cortex and white matter of HIV-1-seropositive patients. They found that microglial cells (and to a much lesser degree, astrocytes) were frequently TNF-ac positive by immunocytochemistry. IL-1lB and IFN--y were detected in virtually all endothelial cells, while TNF-ao-and IL-6-positive endothelial cells were less frequently seen. Interestingly, this group also found that five of seven patients had increased TNF-a levels in the CSF, but again no correlation was found with the presence or absence of CNS involvement. In contrast to Gallo's observation, none of the patients examined in this study had detectable CSF IL-lp levels. In addition, major histocompatibility complex class II-positive CD4+ and CD8+ cells were identified in a perivascular location in the CNS and cited as further evidence that the immune system is activated in the neural parenchyma during HIV-1 infection.
In total, these studies suggest that the cytokine cascade is activated in the meninges and parenchyma of HIV-1-infected patients.
In Vitro Evidence for the Role of Cytokines in HIV-1-Associated Neuropathology Using rat brain cultures, Merrill and colleagues (251) examined the ability of HIV-1 to induce TNF-a and IL-1*. Both a macrophage-tropic and a T-cell-tropic HIV-1 strain induced both cytokines in astrocytes and microglial cells. Productive infection failed to occur, demonstrating that cytokine activation occurs independently of infection in these cells. Heat-inactivated virions, recombinant gpl60, and gp4l induced TNF-a and IL-11, again demonstrating that infection was not a prerequisite for cytokine induction. Similarly, antibodies to epitopes in the gpl20 and gp4l
proteins of the envelope protein blocked the induction.
These results are similar to those of Sundar and colleagues (354) , who found that intracranial injection of gpl20 in the rat CNS resulted in detection of IL-lp in the neural parenchyma. The IL-1B elevation was associated with increased plasma steroid levels and a decrease in cell-mediated immune response. As discussed in a previous section, IL -13 may have caused the steroid elevation by acting at the level of the hypothalamus in the hypothalamic-pituitary-adrenal axis. When gpl20 was infused with alpha-melanocyte-stimulating hormone, a biologic blocker of IL-lp activity, the steroid elevation was blocked.
The results of Merrill and Sundar are in contrast to those of Genis and colleagues (134) , who used human glial cultures (both primary and cell lines). They found that HIV-1-infected monocytes cocultured with astrocytes released elevated levels of TNF-a and IL-1,B. However, in this case the monocyte was demonstrated to be the source of the cytokines. Furthermore, the addition of gradient-concentrated viral particles to the astrocytes failed to induce any cytokines. Genis et al. also demonstrated that a viable monocyteastrocyte interaction was required for induction of the cytokines and that this induction is mediated by arachidonic acid metabolites.
As mentioned in an earlier section, Tornatore and colleagues (361) demonstrated that HIV-1 is able to infect human fetal astrocytes, establishing a persistent state of infection in which HIV-1 expression is undetectable. However, when the persistently infected astrocytes were cocultivated with a T-cell line, a productive phase of infection was reestablished. The ability to reestablish productive infection in the absence of cell-to-cell contact with the T-cell line implicated a soluble factor as a mediator of this induction. TNF-ct and IL-13 alone were subsequently found to induce the productive infection.
Similarly, Swingler and colleagues (356) found that, in cultures of human astrocyte cell lines and primary murine astrocytes, both transfected with an HIV-1 LTR-chloramphenicol acetyltransferase construct, TNF-a and IL-1 activated the LTR-driven gene expression. IL-6 activated the LTR only in the murine cultures, while interferons generally suppressed expression of the LTR. TNF-ao and IL-1B induced an NF-KB-like protein in a neuroblastoma and an astrocytoma cell line, respectively. The protein-bound sequences matching the enhancer of HIV-1 demonstrate that, similar to cells of the lymphatic system, cytokine induction of HIV-1 expression is mediated by NF-KB in brain-derived cells (356) .
These two studies suggest that, in the setting of cytokine induction, the viral burden of the CNS may be amplified by the induced expression of HIV-1 from infected resident cells of the nervous system.
Vitkovic and colleagues demonstrated that media conditioned by either primary rat or human astrocytes or glioma cell lines were capable of stimulating the expression of HIV-1 in a chronically infected promonocyte cell line (365) . The medium from human cells did not contain TNF-ao, nor did an antibody to TNF-a block the expression of HIV-1 by this medium. The medium did, however, contain detectable IL-6 levels, and an antibody to IL-6 blocked the expression of HIV-1 in the monocytes. These results suggest that HIV-1-infected monocytes that gain access to the CNS may have viral expression augmented by CNS-derived cytokines. This augmentation would further contribute to the high viral burden seen in the CNS of HIV-1-infected individuals.
Wahl and colleagues (369) found that the subcortical white matter of four patients with AIDS contained astrocytes and mononuclear cells that expressed transforming growth factor 13 (TGF-,B). While TGF-1 expression was closely associated with areas of apparent tissue pathology, expression was not limited to HIV-1-infected cells, implicating an alternative mechanism for induction of this cytokine. In vitro, HIV-1-infected monocytes released a soluble factor that promoted TGF-,B secretion from noninfected neonatal rat astrocytes. Given that TGF-,B is a chemotactic signal for monocytes, the authors of this study hypothesized that subcortical astrocytes use TGF-1 to provide a signal for the ingress of monocytes into the CNS. The ingress of the monocytes leads to further astrocyte TGF-1 production and possibly a selfperpetuating cycle of monocyte invasion.
Opportunistic Infections
Several opportunistic pathogens contribute to the neuropathology of AIDS. In most cases the neuropathology associated with other viral infections, parasitoses, mycoses, and bacterial infections in the CNS can be distinguished from HIV-1-associated neuropathology. A complete treatment of the neuropathology of the broad range of opportunistic infections complicating AIDS is beyond the scope of this review. The reader is therefore referred elsewhere for this information (1, 111, 144, 227) . 
Neuropsychological Tests
The pattern of neuropsychological performance deficits and reported changes in cognition, motor function, and behavior are consistent with a subcortical dementing process (247) . The most reliable decrement in performance among AIDS patients has been on measures with a substantial motor and psychomotor speed component, although Skoraszewski and colleagues (340) observed that the overall pattern of impairment among AIDS patients includes such higher cortical functions as abstraction, memory, and verbal spontaneity. Others have suggested that HIV-1-induced cognitive dysfunction manifests with more variability, including dementia with cortical deficits, subcortical dementia, and subcortical cognitive deficits in the absence of global intellectual deterioration (86) .
A review of 14 neuropsychological investigations with AIDS-related complex or AIDS patients suggests that language functioning, general knowledge base, and visuospatial-visuoconstructive abilities are spared, while motor and psychomotor tasks, particularly those with a timed component, are reliably impaired (90, 223, 255, 307, 340, 362, 364 (141) . Although some studies have indicated that the presence of CSF HIV-1 p24 antigen is associated with a progressive encephalopathy in children (101, 143) and in some adults (142) , subsequent studies have failed to confirm that the detection of CSF HIV-1 antigen predicts subsequent neurological deterioration (38, 296) . Similarly, the isolation of HIV-1 from CSF is not a useful marker for HIV-1 encephalopathy (38) . The mononuclear pleocytosis observed is generally low, usually with counts of <50 cells per mm3 (265) . Cytological analysis may reveal reactive lymphocytes, plasma cells, and, in rare instances, multinucleated giant cells (185) . The CSF glucose is normal or borderline. Antibody in the serum should be detectable by the time the patient presents with HIV-1 encephalopathy, but both adults (303) and children (305) may present with the encephalopathy before seroconversion.
Cytokines can be detected in the CSF of patients with HIV-1 infection. As discussed earlier, in a study by Gallo and colleagues (119), IL-1i was found in the CSF of 58% of patients with HIV-1 infection and IL-6 was found in 42%. Both cytokines could be detected in the absence of clinical neurological disease but appeared to be detected more frequently in the presence of HIV-1 encephalopathy (119). Other cytokines that are detected in elevated levels in the CSF of some patients with AIDS include the macrophage products TNF-a, neopterin, and 32-microglobulin and the T-cell products soluble CD8 and gamma interferon (363) . In one small series (240) , TNF-a appeared more commonly in patients with moderate to severe HIV-1 encephalopathy than in those with mild disease. However, other investigators have failed to find TNF-a in the CSF of patients with HIV-1 encephalopathy (120). These discrepancies may simply reflect the sensitivity of the assays used.
Elevated 032-microglobulin, a low-molecular-weight protein that is bound to the major histocompatibility protein and expressed on the cell surface of almost all nucleated cells, has been detected in the CSF and is more common in the presence of neurological disease (30, 31, 96, 240) . CSF 32-microglobulin levels do not appear to be proportional to the degree of CSF pleocytosis or to an alteration in the blood-brain barrier (30) . Brew Quinolinic acid, a potent neuroexcitant in the CNS (351) which has also been suggested as a pathogenic mechanism in AIDS dementia complex (158, 159, 204) , is induced in macrophages infected with HIV-1, human herpesvirus 6, and alpha interferon (32) . Increased levels of CSF quinolinic acid have been associated with poorer neuropsychological performance across the spectrum of HIV-1-associated neurological disease (158, 159, 204 The most commonly reported abnormality on CT scan of the brain is cerebral atrophy (39, 216, 265, 266) . A correlation between neuropsychological function, namely, a slowing of response time and severity of brain atrophy determined by cerebral ventricular enlargement on CT scan (175) and on MRI (213) , has been observed. Additionally, a correlation between brain atrophy on MRI and the presence of HIV in CSF and elevated levels of 02-microglobulin has been demonstrated (345) . On CT scan, white matter lesions are infrequently observed, but their detection is increased dramatically by the increased sensitivity of MRI for white matter disease. Olsen and colleagues (279) noted that the most commonly observed pattern of white matter disorder visualized on MRI in HIV-1 encephalopathy was "diffuse," a widespread involvement of a large area. Less commonly observed patterns were characterized as "patchy," localized involvement with ill-defined margins, and "punctate," small foci of <1 cm in diameter (279 (167) . Single-photon emission tomography and PET have been proposed as potentially useful methods to study the progression of HIV-1 encephalopathy (203) .
Lastly, as a correlate of the neuronal loss detected with quantitative morphometry, studies employing proton magnetic resonance spectroscopy reveal significant reductions in levels of N-acetyl aspartate relative to creatine and elevations in choline-containing compounds relative to creatine in patients with moderate to severe HIV-1 encephalopathy (249) . N-Acetyl aspartate is a metabolic marker for normal neuronal function, and its decrease relative to creatine suggests neuronal loss in this disorder. The alteration of the choline/creatine ratio is possibly the result of changes in membrane metabolism (249 (21) . Tinuper and colleagues (360) found no definitely abnormal EEG tracings in neurologically asymptomatic, HIV-1-infected individuals, but they detected "borderline" abnormalities in 33% which they thought required prospective evaluation. In another series, the most common EEG abnormality seen was an increased amount of generalized episodic or persistent, predominantly anterior, slow wave activity (99, 117) . Other abnormalities included a lower maximal amplitude of dominant background activity and more marked generalized and anterior disturbances on EEG in early HIV-1 infection compared with uninfected controls (99) . However, in a series from the multicenter AIDS cohort study, no EEG abnormalities could be attributed to HIV-1 infection in otherwise asymptomatic individuals (274) . Computerized spectral analysis of the EEG has also been used in this regard (173, 281, 282) and may be more sensitive than routine EEG (282) .
Other electrophysiological techniques that have been used to study HIV-1 encephalopathy include brain stem auditory evoked potentials and event-related brain potentials. Brain stem auditory evoked potential studies have detected significant delays in waveforms I-V and III-V in HIV-1-infected individuals compared with controls, indicating abnormalities in the upper brain stem (280, 315) . Multiple regression analysis in those studies has failed to reveal a significant influence of other factors, such as medical history or drug use, on these waveforms (94) . Studies employing cognitive event-related potentials have also shown a delayed response time (8, 278) , suggesting their value in detecting early cognitive disease. However, like EEGs, these studies still remain unproven predictors of the presence or progression of HIV-1 encephalopathy. (196) . The CSF-to-plasma ratios vary between 135% following an oral administration of 15 mg/kg to 15% at an oral dose of 2 mg/kg (196) . However, brain tissue levels may not be adequately reflected by CSF levels of the drug. In AIDS patients treated with this antiretroviral agent, extracellular hyaline globules that show the presence of zidovudine isomers on high-performance liquid chromatography have been detected in the white matter of the brain and spinal cord (10) .
In light of its penetration of the blood-brain barrier and efficacy as an antiretroviral agent, it is not unexpected that zidovudine might prove effective in the treatment of patients with HIV-1 encephalopathy. Indeed, a decline in the overall incidence of HIV-1 encephalopathy was noted after the introduction of zidovudine (295) . Initial anecdotal clinical reports (166, 281) demonstrated improvement in HIV-1 encephalopathy in adults with zidovudine use. These impressions were shortly confirmed by more comprehensive studies (325) . Both the smaller study by Price and colleagues (302) and the larger one by Schmitt and colleagues (325) showed only partial improvement in neuropsychological abnormalities associated with HIV-1. Parallel studies of the effect of zidovudine on brain metabolic abnormalities with HIV-1 encephalopathy have demonstrated that large focal cortical abnormalities of glucose utilization detected by PET utilizing FDG could be reversed (35) and that CSF 12-microglobulin decreases (31) . Further studies to confirm the value of zidovudine in this condition may be difficult to perform because of its early use in the course of infection. An interesting observation by Helbert and colleagues was the appearance of an acute meningoencephalitis in 4 of 21 patients with AIDS or AIDS-related complex within 17 days of dose reduction of zidvudine because of myelotoxicity (157) . Three of the four patients had prior evidence of HIV-1 encephalopathy (157).
In children, a similar and perhaps more dramatic improvement in encephalopathy was demonstrated by Pizzo and colleagues with the use of continuous-infusion zidovudine (291) . In that study, neuropsychological improvement occurred in all patients with evidence of HIV-1 encephalopathy prior to the administration of zidovudine, and in some, the improvement was noted despite the absence of improvement in immunological parameters (291) . The optimal intravenous dose of zidovudine in children appeared to be between 0.9 and 1.4 mg/kg per h (291) .
Whether other antiretroviral therapies will prove as effective as zidovudine in the treatment of HIV-1 encephalopathy remains unanswered. Neither dideoxyinosine nor dideoxycytosine appears to cross the blood-brain barrier as well as zidovudine. Drugs that do not have a primary effect on HIV-1, such as CNS stimulants (methylphenidate and dexedrine) and corticosteroids, have been used in a limited and nonrigorous fashion in attempts at symptomatic improvement of HIV-1 encephalopathy. Anecdotally, prednisone has been reported to improve HIV-1 encephalopathy in children (349) . No data are available regarding its value in adults with this disorder. Although there are legitimate concerns relative to the potential deleterious effect of corticosteroids on HIV-1-infected patients with an already compromised immune system, one study of HIV-1-infected children receiving prednisone showed no consistent or significant change in the number or percentage of CD3, CD4, CD8, or CD19 lymphocytes (322) . CONCLUSIONS The ability of HIV-1 to infect and destroy cells of the host immune system is of paramount importance in the pathogenesis of AIDS. The principal cause of death in AIDS patients is due to complications associated with the uncontrolled multiplication of opportunistic pathogens that manifest themselves in the presence of a weakened immune system. Although opportunistic infections also give rise to neurological complications associated with AIDS, in general, these pathologies are separable from HIV-1-associated neuropathology. This is apparent when one considers that HIV-1-associated neurological disease can occur in the absence of opportunistic infection.
A broad spectrum of neuropathological findings, which includes diffuse damage to white matter with myelin loss, reactive astrogliosis, thinning of the neocortex, loss of synaptic density, and vacuolation of dendritic processes, is associated with HIV-1 infection in the CNS. In vivo evidence of direct HIV-1 infection of neural cells has been limited. Virus is most often detected in macrophages that have invaded brain parenchyma or in microglial cells. Since it is hard to imagine how direct virus multiplication in macrophages and microglial cells can give rise to the broad spectrum of neurological disease just described, indirect mechanisms of damage to neural elements have been proposed. Damage caused by a variety of virally encoded proteins, including Nef, Tat, gp4l, and gpl20, has been proposed to contribute to HIV-1-associated neuropathology. In addition, damage caused by the elaboration of TNF-a by macrophages, microglia, and astrocytes has been proposed to cause the demyelination of neurons in the CNS. Macrophages and microglial cells also have been shown to secrete quinolinic acid, a potent neurotoxin, which may also damage neurons. Elaboration of TNF-a, IL-113, and IL-6 by astrocytes and microglia may act to amplify HIV-1 multiplication in infiltrating macrophages. Conversely, TNF-a and IL-11 released by macrophages may act to amplify HIV-1 multiplication in microglial cells and to reactivate HIV-1 in latently infected astrocytes.
The extent to which each of these mechanisms damages nervous system elements is far from clear. There may, in fact, be additional mechanisms of damage that have either eluded investigators or simply received little attention. For example, the elaboration of toxic components of the complement system are known to cause bystander injury to cells surrounding inflamed tissue. It is possible that some of these components are elaborated in the CNS by infiltrating cells of the immune system or perhaps by resident cells in the CNS such as microglial cells. The roles of natural killer cells and cytotoxic T cells in HIV-1 infection in the CNS are also not known. As we learn more about the control of immune reactivity in the CNS environment, we will no doubt gain a better understanding of how viruses such as HIV-1 cause neurological disease.
The mechanism by which HIV-1 gains access to the CNS is also not known. Since HIV-1 is a highly cell Fig. 3 .
